Genetic resistance is usually the most cost-effective method of controlling crop disease. Qualitative disease resistance confers high levels of resistance, is typically race-specific and controlled by one or few genes with major effects ([@bib7]). By contrast, quantitative disease resistance (QDR) causes a partial reduction in disease symptoms, is usually controlled by multiple genes with relatively small effects and is often not specific to particular pathogen races ([@bib35]; [@bib46]). QDR is thought to be more durable than qualitative resistance because it relies on the resistance mechanisms associated with many different genes, each of which exerts a relatively small selection pressure on pathogens ([@bib1]).

Multiple disease resistance (MDR) loci, defined as "loci that confer resistance to two or more diseases" ([@bib34]; [@bib43]), can be due to distinct linked genes, each associated with resistance to one disease, or to an individual allele that confers resistance to more than one disease (pleiotropy). Colocalization of QTL for resistance to Southern leaf blight (SLB), Northern leaf blight (NLB) and Gray leaf spot (GLS) diseases, caused by the fungi *Cochliobolus heterostrophus*, *Setosphaeria turcica* and *Cercospora zeae-maydis*/*Cercospora zeina*, respectively, has been reported in maize ([@bib4]; [@bib49]; [@bib45]; [@bib6]; [@bib28]; [@bib30]). These diseases are among the most important foliar diseases of maize worldwide ([@bib32]). The pathogens are all ascomycete fungi in the dothideomycete class that share a largely necrotrophic lifestyle (although *S. turcica* has been described as a hemi-biotroph). One gene associated with detoxification ([@bib45]) and another involved in lignin biosynthesis ([@bib47]) appear to confer resistance to all three diseases.

[@bib45] found high positive genetic correlations between resistance to these diseases in a maize association mapping panel of 253 maize inbred lines ([@bib13]). Linkage disequilibrium in this population is very low, reducing the chances that the correlations among resistances were due to linkage rather than pleiotropy. Several MDR and multiple disease susceptible (MDS) lines were selected from this population for the development of populations designed for the mapping and characterization of MDR loci. We developed a set of BC~3~F~4:5~ chromosome segment substitution line (CSSL) populations in which segments from four of these MDR donor lines were introgressed in the backgrounds of two multiple disease susceptible (MDS) lines ([@bib30]). Disease resistance QTL were identified in these populations, some associated with resistance to two or three diseases ([@bib29]; [@bib30]).

The use of CSSL mapping populations allows for the comparison of QTL in a common background and facilitates follow up studies of specific alleles of interest. Since a particular donor allele is present in only a few lines in a CSSL population, however, effect estimates are prone to greater inaccuracy than in biparental mapping populations, where contrasting alleles are present at approximately equal frequencies. Also, since the lines are nearly completely homozygous, it is not possible to estimate dominance effects ([@bib21]; [@bib22]; [@bib18]).

The goal of this study was to independently test the significance, and more precisely estimate the additive and dominance effects of some of the previously-identified disease resistance QTL ([@bib29]), especially those associated with MDR. Twelve F~2:3~ populations were made from crosses between CSSL with the strongest resistance across the three diseases and their recurrent parent, H100. The resulting populations were assessed for each of the three diseases in replicated trials.

Materials and methods {#s1}
=====================

Populations {#s2}
-----------

As part of a previous study ([@bib30]), four chromosome segment substitution populations (BC~3~F~4:5~ lines) were created by crossing four multiple disease resistance maize (*Zea mays*) lines, Ki3, NC262, NC304, and NC344 as donors, with the disease susceptible lines H100 and Oh7B, as the recurrent parent. An identification code was ascribed to each line, starting with the prefix DRIL (for "Disease Resistance Introgression Line") followed by the population code followed by a specific line number. The line codes were: Ki3 = 3, NC262 = 5, NC304 = 6, NC344 = 7, H100 = 2, Oh7B = 8). In each case, the code number for the donor parent is first and the number for the recurrent parent is second, so, for instance, 32 and 52, meant Ki3/H100 and NC262/H100 populations respectively. The final populations were genotyped using Pioneer Illumina publicplex platform with 765 SNP markers ([@bib20]) with 245-271 informative SNPs within each population ([@bib30]). All the populations were evaluated for SLB, NLB, and GLS in replicated trials in two locations.

For this study, twelve DRIL lines with H100 as the recurrent parent that showed strong resistance to all three diseases were chosen and crossed with H100 to generate F~2:3~ families ([Figure 1](#fig1){ref-type="fig"}, [Table 1](#t1){ref-type="table"}).

![Scheme used to produce populations of F~2:3~ families and the QTL segregation within line.](2905f1){#fig1}

###### F~2:3~ populations were derived from crosses between disease-resistant near-isogenic (DRIL) lines that had previously been identified as highly multiply disease resistant ([@bib29]) and H100, the original susceptible recurrent parent used to construct the DRILs. Original donor parent indicates the original resistant parent used for the production of the DRIL lines (the original source of all the non-H100 alleles segregating in the F~2:3~ population). The number of F~2:3~ families created, and number of distinct introgressions previously associated with disease resistance segregating in each population are also presented

  F~2:3~ Population name   Susceptible parent   DRIL parent   Original donor parent   Number of F~2:3~ families created   Number of introgressions
  ------------------------ -------------------- ------------- ----------------------- ----------------------------------- --------------------------
  H100_DRIL_32.090         H100                 DRIL_32.090   Ki3                     70                                  2
  H100_DRIL_32.095         H100                 DRIL_32.095   Ki3                     86                                  2
  H100_DRIL_32.134         H100                 DRIL_32.134   Ki3                     63                                  2
  H100_DRIL_32.191         H100                 DRIL_32.191   Ki3                     86                                  1
  H100_DRIL_52.055         H100                 DRIL_52.055   NC262                   68                                  3
  H100_DRIL_52.157         H100                 DRIL_52.157   NC262                   101                                 1
  H100_DRIL_52.268         H100                 DRIL_52.268   NC262                   77                                  3
  H100_DRIL_62.030         H100                 DRIL_62.030   NC304                   49                                  1
  H100_DRIL_62.078         H100                 DRIL_62.078   NC304                   87                                  2
  H100_DRIL_62.156         H100                 DRIL_62.156   NC304                   63                                  2
  H100_DRIL_72.061         H100                 DRIL_72.061   NC344                   79                                  2
  H100_DRIL_72.232         H100                 DRIL_72.232   NC344                   63                                  1

Experimental design {#s3}
-------------------

Twelve populations, varying from 49 to 101 F~2:3~ families ([Table 1](#t1){ref-type="table"}) were tested in replicated trials for each of the diseases: SLB, NLB, and GLS. Each experiment had an augmented compete block design, with the population as block. The recurrent susceptible parent H100 was included at a random location within each sub-block of 21 plots, and each MDR parent was planted once in its respective population.

During the summer of 2017, two complete replications of 1029 plots each were planted for the evaluation of SLB in Central Crops Research Station (CCRS) Clayton NC; two complete replications were planted in Blacksburg VA, College Farm Research Station, for the evaluation of GLS; and one incomplete replication consisting of 700 plots, was planted in Andrews NC for the evaluation of GLS. During summer 2018, two complete replications were planted in CCRS, Clayton NC, for the evaluation of NLB.

Inoculation preparation and inoculum procedure {#s4}
----------------------------------------------

The inoculum was prepared as previously described ([@bib39]). Briefly, sorghum kernels were soaked in water for 3-4 days, autoclaved for one hour, allowed to cool overnight and inoculated with either *C. heterostrophus*, *S. turcica*, or *C. zeae-maydis*. The fungus was grown at room temperature (23-25°) for at least 10 days until the sorghum was colonized. The fungus-infested sorghum was air-dried and stored at 4°. 30-40 day old maize plants were inoculated by adding 6-10 infested sorghum kernels into the whorl of each maize plant.

Genotyping {#s5}
----------

Tips of leaves were collected from 5 adult plants per F~2:3~ family, bulked, and lyophilized. The samples were sent to Agriplex Genomics for DNA extraction and genotyping. For each population, only markers known to be segregating and that were associated with resistance to one or more diseases in the previous study ([@bib30]) were genotyped. Primers were designed based on the context sequence of the SNPs reported by Lopez-Zuniga (2016) using the B73 reference genome version 3. (Table S1). All the genotypic data used are available in File S1. Genetic map positions are based on the IBM4 genetic map ([@bib15]).

Phenotypic evaluation of SLB {#s6}
----------------------------

The experiment was planted in a single field, with 8 seeds per plot, in 1.8-m single rows with 0.9-m row width. Inoculations of SLB were performed 40 days after planting, using *C. heterostrophus* isolates, including 2-16Bm and Hm540 ([@bib10]). Visual scores were taken three times at 10 days interval, starting 77 days after planting, when the plants were in the developmental stage R2. The scoring used a scale of 1 to 9, where 1 is dead and 9 is immune ([@bib39]). Each plot had one score given at each evaluation. If the plot was segregating it was given a score that represented the average disease severity of the plot. For each plot in both replications, days to anthesis (DTA) was recorded when half the plants in a plot were shedding pollen. File S2 includes all the SLB scoring data.

Phenotypic evaluation of NLB {#s7}
----------------------------

All field evaluations of NLB were performed during summer growing season of 2018, with two replicates grown at CCRS in Clayton, NC. The experiment was planted in the same fashion as the SLB trial. Inoculations of NLB were performed 26 days after planting, using several *Exserohilum turicum* isolates (race 0, race 1, race 2,3 and race 2,3,N). Visual scores were taken three times at six to eleven days interval, starting 64 days after planting. NLB was scored using the percentage of diseased leaf area, from 0 to 100. A single score was ascribed to each plot at each evaluation. If the plot was segregating it was given a score that represented the average disease severity of the plot. The disease scores were converted to fit the same scale of GLS and SLB (1 to 9). For each plot in both replications, days to anthesis (DTA) was recorded when half the plants in a plot were shedding pollen. File S3 includes all the NLB scoring data.

Phenotypic evaluation of GLS {#s8}
----------------------------

All field evaluations of GLS were performed during the summer growing season of 2017, with two replicates at College Farm Research Station in Blacksburg, VA and an incomplete replicate in Andrews, NC. Trials were planted in 4-m single rows with a 1-m row width using 15 seeds per plot, in both locations. Inoculation was performed in the field in Virginia 30 days after planting, using a mixture of several *Cercospora maydis* inoculum isolates. No artificial inoculation was done in Andrews since the field contained infected plant debris from previous years that provided a high disease pressure. Visual scores were taken twice at each location using a scale of 1 to 9, where 1 is dead and 9 is immune A single score was ascribed to each plot at each evaluation. If the plot was segregating it was given a score that represented the average disease severity of the plot. Scores were recorded with the Field Book application ([@bib38]) File S4 includes all the GLS scoring data.

Statistical analysis {#s9}
--------------------

### Phenotypic data: {#s10}

Exploratory phenotypic data analysis was performed using Statistical Analysis System (SAS) v9.4 software (SAS Institute Inc., Cary, NC), Tableau v9.1 and R (R core development team 2015). We did not find any outlying data points that warranted removal. Heat maps were produced to visualize any disease severity spatial pattern in the field and box plots were created to check the severity of disease in the F~2:3~ lines in comparison to the susceptible and resistant checks. Correlation coefficients between disease scores of lines measured in different replications or on different diseases were calculated.

For each disease trial, using two to three disease scores collected at different time points, the standardized area under disease progress curve (sAUDPC) was calculated for each plot by taking the average value of two consecutive ratings and multiplying by the number of days between the ratings. Values were then summed over all the intervals and then adjusted by dividing by the number of days between evaluations, so that the sAUDPC scores are on a similar one to nine scale as the initial ratings ([@bib9]).

Statistical analysis was performed using the MIXED procedure in SAS. To adjust the least square means (LSMeans) for field effects, range and column of the field position for each plot were added to the model as random effects. The mixed linear model used to analyze data from the SLB trials was$$y_{ijkmn} = \mu + L_{i~} + ~D_{j}~ + ~R_{k} + G_{m}~ + ~C_{n} + ~\varepsilon_{ijknm}~~$$where y is the response variable SLB sAUDPC, *L~i~* is the fixed effect of the *i*^th^ line, *D~j~* is the fixed effect of number *j^th^* of days to anthesis (DTA), *R~k~* is the random effect of the *k*^th^ replicate, *G~m~* is the random effect of the *m*^th^ range, *C~n~* is the random effect of the *n*^th^ column. A similar model was used to analyze data from the NLB trial:$$y_{ijkmn} = \mu + L_{i~} + ~D_{j}~ + ~R_{k} + G{(R)}_{m(k)}~ + ~C{(R)}_{n(k)} + ~\varepsilon_{ijknm}~~$$the response variable y was NLB AUDPC, *L~i~* is the fixed effect of the *i*^th^ line, *D~j~* is the fixed effect of number *j^th^* of days to anthesis (DTA), *R~k~* is the random effect of the *k*^th^ replicate, *G(R)~m(k)~* is the random effect of the *m*^th^ range nested in *k*^th^ replicate, *C(R)~n(k)~* is the random effect of the *n*^th^ column nested in *k*^th^ replicate. To analyze the data from the GLS field trial, the model used was$$y_{ijkmn} = \mu + L_{i~} + ~O_{j}~ + ~R{(O)}_{k(j)} + G{(O)}_{m(j)}~ + ~C{(O)}_{n(j)} + ~\varepsilon_{ijknm}$$where **y** is the response variable GLS AUDPC, *L~i~* is the fixed effect of the *i*^th^ line, *O* is the random effect of *j^th^* location, *R(O)*~k(j)~ is the random effect of *k*^th^ replicate nested in *j^th^* location, *G(O)~m(j)~* is the random effect of *m^ith^* range nested in *j^th^* location, *C(O)* is the random effect of *n^th^* column nested in *j^th^* location. LSMeans for each line and disease were calculated from the model.

Heritability on a plot and entry-mean basis for each disease were calculated as described previously ([@bib17]) using the variance components described above and a harmonic mean for the number of replicates per entry. We used combined data from all populations to estimate heritability.

Genotypic data {#s11}
--------------

A Chi-square test was performed for each marker within each population to assess if the segregation was significantly different from the expected 1:2:1. Markers whose segregation was significantly different to expectation were removed from the study.

Each marker was tested separately by multiple regression of F~2:3~ family LSMeans as observations on coefficients representing the additive and dominance effects at the marker using SAS PROC MIXED. Additive coefficients represented the number of resistant parent alleles (0, 1, or 2) at the locus in the F~2~ founder plant of each family. Dominance coefficients were 0 for both homozygous classes and 1 for heterozygotes. Marker additive effects were estimated directly from the additive regression coefficient; dominance effects were estimated as twice the dominance regression coefficient because only half of the individuals in the segregating lines are expected to be heterozygous. Type III F-tests of additive and dominance regression coefficients were used to declare significant marker effects at α=0.05. If more than one marker was significant in the same bin and less than 20 cM apart, the marker that had the smallest P-value, or had a significant effect for the greatest number of diseases, was chosen to represent the effect of that QTL ([Table 2](#t2){ref-type="table"}, Table S2). In cases where the population was segregating for more than one unlinked marker, marker interactions were tested by fitting the two markers and their interaction in the model using PROC GLM to verify epistasis. If there was no interaction, a third model was run with PROC GLM, fitting the main effects of the two markers as fixed effects and the disease LSMeans as the response to obtain simultaneous estimates of the two marker effects.

###### Results from selected markers to represent each introgression. Multiple disease resistant donor line (Donor), code name of NIL parent carrying target introgression and crossed to H100 to form F~2:3~ families for validation, marker, chromosome (Chr) and genetic bin, genetic position (cM) based on the IBM4 genetic map, trait and additive effect estimate ($\hat{a}$) previously associated with the marker ([@bib29]), disease, additive effect ($\hat{a}$), dominance effect ($\hat{d}$), and trait(s) for which QTL effect was validated by this study. Non-significant dominance effect are denoted as NS. All reported marker effects are significant at *P* = 0.05

                                                                  QTL effect detected in previous study   Significant QTL effects detected in current study                              
  ------------ ------------ ------------- ------- --------------- --------------------------------------- --------------------------------------------------- ------- ------- ---------- ----------
  Ki3          DRIL32.090   PHM3457-6     2.05    96.4            MDR                                     0.39                                                GLS     0.18    NS         MDR
  NLB          0.07         NS                                                                                                                                                           
  DRIL32.090   PZA00379-2   8.03          59.5    MDR, SLB        0.27, 0.28                              SLB                                                 0.16    NS      MDR, SLB   
  NLB          0.10         NS                                                                                                                                                           
  DRIL32.095   PZA01886-1   9.04          114.7   MDR, SLB        0.50, 0.29                              SLB                                                 0.30    NS      SLB        
  DRIL32.134   PZA00485-2   2.05          99.1                                                            GLS                                                 0.28    NS                 
  DRIL32.134   PHM4757-14   8.03          89.8    MDR, GLS, NLB   0.24, 0.16, -2.73                       NLB                                                 0.13    NS      NLB        
  DRIL32.191   PHM4495-14   9.03          59.0    MDR, SLB        0.36, 0.25                              NLB                                                 0.05    NS                 
  NC262        DRIL52.055   PZA03577-1    2.07    195.7           MDR                                     0.36                                                SLB     −0.19   NS         
  DRIL52.055   PZA00060-2   9.04          114.5   MDR             0.33                                    SLB                                                 0.18    NS      MDR        
  NLB          0.03         NS                                                                                                                                                           
  DRIL52.268   PZA03577-1   2.07          195.7   MDR             0.36                                    GLS                                                 0.13    NS                 
  DRIL52.268   PHM4757-14   8.03          98.8    GLS             0.35                                    GLS                                                 −0.11   NS                 
  NC304        DRIL62.030   PHM13420-11   3.04    92.1            MDR, GLS                                0.54, 0.17                                          GLS     0.32    NS         GLS
  NC304        DRIL62.078   PHM9635-30    4.05    96.0            GLS                                     0.17                                                GLS     0.26    NS         GLS
  NLB          0.05         NS                                                                                                                                                           
  NC304        DRIL62.078   PZA02209-2    5.04    124.0           MDR                                     0.25                                                GLS     0.15    NS         MDR
  SLB          0.14         NS                                                                                                                                                           
  NLB          0.06         NS                                                                                                                                                           
  NC304        DRIL62.156   PHM13420-11   3.04    92.1            MDR, GLS                                0.54, 0.17                                          GLS     0.27    NS         MDR, GLS
  SLB          0.43         NS                                                                                                                                                           
  NLB          0.08         0.14                                                                                                                                                         
  NC344        DRIL72.061   PHM14412-4    2.05    127.4           MDR, GLS                                0.30, 0.16                                          GLS     0.27    0.54       GLS
  NC344        DRIL72.061   PZA00667-1    3.04    96.7            MDR                                     0.35                                                SLB     0.21    NS         MDR
  NLB          0.07         NS                                                                                                                                                           
  NC344        DRIL72.232   PHM4586-12    2.05    79.3            GLS                                     0.14                                                NLB     −0.07   NS         

Data availability {#s12}
-----------------

All phenotypic and genotypic data used in this study are included in Files S1-4. In many cases very little seed remains of F~2:3~ families used. However F~2~ populations are available upon request. The original DRILs are available at the maize genetic stock center (<https://maizegdb.org/data_center/stock?id=9039691>).

All phenotypic and genotypic data used in this study are available in the supplementary files. Further information is available from the corresponding authors if required. Supplemental material available at FigShare: <https://doi.org/10.25387/g3.7887698>.

Results and Discussion {#s13}
======================

Twelve F~2:3~ populations developed from crosses between 12 selected disease resistant lines and the susceptible parent H100 were created ([Figure 1](#fig1){ref-type="fig"}, [Table 1](#t1){ref-type="table"}). These populations were evaluated in replicated trials for SLB, NLB and GLS resistance. Correlations between replications were all highly significant. Heritabilities on a plot-basis were 0.45, 0.29, and 0.36 and on an entry-mean basis were 0.57, 0.49, and 0.52 for SLB, GLS, and NLB, respectively. Pairwise phenotypic correlations across all the populations for resistance to the three diseases were moderate but highly significant ranging from *r* = 0.2 to 0.3 (*P*-value \<0.01). The pairwise disease resistance correlations within individual populations were often but not always significant (Table S3). Correlation and heritability estimates were relatively moderate due partly to the nature of these populations. Each population was only segregating at a small number of loci and therefore captured less genetic variation than typically seen in RIL populations or association panels, for which a large proportion of the genome is variable.

The fixed effects of line and DTA (when DTA data were available) were significant for all diseases. For all field trials, range and column field effects were significant but replicate was never significant (Table S4). The only disease that had field trials in different locations was GLS and the effect of location was not significant.

Each of the 12 DRILs selected as the parents of the 12 F~2:3~ populations carried multiple introgressions. Of these, between one and three introgressions had been previously associated with resistance to at least one disease or the MDR composite score in our previous analyses ([@bib29]). We followed the segregation of all of these previously associated introgressions for all subsequent analyses, but we did not follow the segregation of any introgressions that were segregating in the population that had not been associated with resistance to any disease in the original analysis.

We genotyped 28 markers (Table S1) to examine the segregation of 24 introgressions across the twelve F~2:3~ family populations ([Table 1](#t1){ref-type="table"}). Each population was segregating at one to five of these markers/introgressions. We assessed the association of each segregating marker with resistance to each disease regardless of which disease(s) it had been associated with in the previous study. In total, associations between 66 QTL-disease combinations (with some QTL represented by more than one marker) were tested. In cases in which more than one marker was used to follow the segregation of a single introgression, we selected the marker most strongly associated with disease resistance as the marker to represent the QTL in that introgression for further analyses (Table S2). The QTL was considered validated if it had the same directional allele effect on any of the diseases as was found previously ([@bib29]). In cases where two markers representing different introgressions were both significant for a specific disease/population combination, both were incorporated in a final model to calculate effect sizes to account for any potential epistatic effects, though ultimately no epistatic effects were detected.

After selecting only one marker for each introgression, we were able to test 44 previously identified QTL, 20 associated with the MDR composite score and 24 with single disease resistance, several of which co-localize (Table S2). The effects of 16 out of these 44 previously identified QTL were validated. [Table 2](#t2){ref-type="table"} summarizes the significant marker/disease resistance associations that were detected. An MDR QTL that was previously detected with the composite score ([@bib29]) was considered validated when it was significant for more than one disease. In some cases, the same QTL was validated for MDR and single disease resistance. In the original analysis, MDR QTL were detected using an initial analysis based on a composite score (equally weighted index) derived from the average of the trait values of the three diseases ([@bib29]). Subsequent to the development of the populations for this study, an alternative analysis of the original CSSL populations was performed using a composite statistic, *Md*, which accounts for covariance between the QTL test results for each trait ([@bib30]). The MDR loci that were targeted in the present study were identified based on the original MDR QTL analysis ([@bib29]). Of the 20 MDR alleles tested over all the populations (Table S2), 18 were also identified as MDR alleles in the analysis with the *Md* statistic. Of the two alleles not detected using the *Md* statistic, (PHM3457-6/Ki3 and PZA03577-1/NC262) one (PHM3457-6/Ki3) was validated for MDR in this study ([Table 2](#t2){ref-type="table"}, Table S2).

Considering multiple and single diseases, we identified 33 marker-disease associations in this study. Since 16 of these were validations of previously identified QTL, that means that 17 were not identified in the previous analysis of the CSSL populations ([@bib30]). For example, marker PHM4586-12 in population H100_DRIL72.232 was previously associated with GLS but in the current study was significant for NLB. Marker PHM4495-14 in population H100_DRIL32.191 was previously associated with SLB but in the present study, it was significant for NLB.

Dominance was observed only in two cases out of the 26 instances where we observed a significant marker-trait association: marker PHM13420-11 in population H100_DRIL62.156 and marker PHM14412-4 in population H100_DRIL72.061 ([Table 2](#t2){ref-type="table"}). In both cases the allele conferring resistance was dominant. This relative rarity of dominance effects may be partially due to the low power with which we are able to detect them; only half the plants in an F~2:3~ family that is derived from a heterozygous parent are themselves heterozygous, so only half the full dominance effect can be observed and thus dominance is harder to observe than if we were comparing fully homozygous and fully heterozygous families. It may also be the case that QDR alleles tend not to show dominance effects. It is hard to determine from the literature whether this is the case as most studies have been conducted with RIL populations from which no dominance effects can be calculated

While alleles from the MDR parent conferred resistance as expected in most cases, in three of 26 cases, alleles from the donor MDR parent were associated with disease susceptibility. The NC262 allele at marker 2PZA03577-1 carried a susceptibility allele for SLB in population H100_DRIL52.055, the NC262 allele at marker PHM4757-14 conferred susceptibility to GLS in population H100_DRIL52.268 and the NC344 allele at marker PHM4586-12 conferred susceptibility to NLB in population H100_DRIL72.232 ([Table 2](#t2){ref-type="table"}). It is not surprising that a few resistance alleles derived from the susceptible parent. This phenomenon has been observed a number of times in our previous studies (*e.g.*, [@bib5]).

Possible reasons why fewer than half the QTL were validated are associated with the design of both the original study and this validation study. The low minor allele frequency in the original CSSL mapping populations, an inherent feature of these populations, might have caused inaccuracies since each minor allele was only sampled a handful of times in each population. Also, since the genotyping of the original populations was not dense (209-271 markers in each population) it is possible that some introgressions that affected disease resistance were not accounted for, which may have led to greater errors in the analysis. In the current study, the number of F~2:3~ families used in each population was between 49 and 101 ([Table 1](#t1){ref-type="table"}), a relatively low number of families which may not have provided enough power to detect QTL of modest effect. We noted previously ([@bib30]) that the detection of an MDR locus could be driven by a strong effect on one disease and little or no effect on the others. In this study, we deliberately took a more stringent approach, only declaring an MDR QTL if it had a significant effect on more than one individual disease. In several cases, a marker previously associated with MDR was associated with resistance to only one disease and so by our criteria, it was not considered to be validated. For example, marker PHM14412-4 on population H100_DRIL72.061 was associated with GLS and MDR previously but was validated only for GLS ([Table 2](#t2){ref-type="table"}). In cases like this, it is likely that the original MDR QTL might have been identified due to strong effects on one disease (GLS) in this case rather than to moderate effects on multiple diseases. In fact, most of the QTL identified using the *Md* statistic had effects strongly skewed toward one disease ([@bib30]). Conversely, the new marker/disease associations identified in this study likely occurred because the F~2:3~ populations had more power to test associations due to a higher representation of the minor allele.

In some cases, the same allele was significant for the same disease in different populations. Marker PHM13420-11 associated with an allele from NC304 was validated for GLS in population H100_DRIL62.030 and for GLS and MDR in population H100_DRIL62.156 ([Table 2](#t2){ref-type="table"}). In these cases, the fact that it was validated in distinct F~2:3~ populations increases our confidence in the association of this marker and GLS resistance. On the other hand, there were instances where the same allele was segregating in two populations but the results from single marker analysis differed. For example, Marker PHM3457-6 was significant for all three diseases in H100_DRIL32.090 and only for GLS in H100_DRIL32.134 ([Table 2](#t2){ref-type="table"}). This could have occurred due to the type of experimental errors described above or possibly the marker may have been linked to the causal gene in one population but may have become unlinked in another due to a recombination event occurring during the development of the parental DRIL.

The main goal of this study was to validate and characterize robust MDR alleles. Of the six alleles validated for MDR, two were associated with resistance to all three diseases; in population H100_DRIL62.078, marker PZA02209-2, bin 5.04 and in population H100_DRIL62.156, marker PHM13420-11, bin 3.04. In both cases the resistance alleles derived from the maize line NC304. Both loci have been previously identified as QTL for all three diseases ([Table 3](#t3){ref-type="table"}). However, in none of these cases was the same allele associated with resistance to all three diseases. Previous meta-analyses of maize QTL have also identified bin 3.04 as a disease resistance QTL hotspot ([@bib31]; [@bib44]; [@bib2]).

###### Summary of QTL for SLB, NLB and GLS identified in previous studies in bins 3.04 and 5.04. Table includes BIN, marker, chromosome (Chr), population type (pop), disease (Dis), mapping method (Method) and reference

  BIN         Marker                   Pop                                    Dis   Method   Reference
  ----------- ------------------------ -------------------------------------- ----- -------- ----------------------
  3.03/3.04   asg48-phi036             B73\*Mo17 (RILs)                       SLB   CIM      ([@bib11])
  3.04        UMC10                    F2:3, ADENT\*B73rhm                    GLS   SIM      ([@bib8])
  3.04        PIO200508                F2:3, ADENT\*B73rhm                    GLS   SIM      ([@bib8])
  3.04        BNL10.24                 F2:3, ADENT\*B73rhm                    GLS   SIM      ([@bib8])
  3.04        us41                     Propietary F2                          GLS   CIM      ([@bib24])
  3.04        PHM4621.57               NAM                                    NLB   GWAS     ([@bib37]; [@bib28])
  3.04        phi036-bnlg602           NC300\*B104 (RILs)                     SLB   MIM      ([@bib3])
  3.04        PZA02077                 NILs, Teosinte\*B73                    SLB   LA       ([@bib25])
  3.04        PZA00828                 NILs, Teosinte\*B73                    SLB   LA       ([@bib25])
  3.04        PHM4145_18               B73\*CML254, B97\*CML254/Ki14 (RILs)   SLB   JL       ([@bib33])
  3.04        umc2275-umc2008          T14\*T4 F2:3                           SLB   CIM      ([@bib36])
  3.04        umc2275-umc2008          T14\*T4 F2:3                           SLB   CIM      ([@bib36])
  3.04        npi446-umc2000           B73\*Mo17 (AIRIL)                      SLB   CIM      ([@bib5])
  3.04        mmp69-umc1920            B73\*Mo17 (AIRIL)                      SLB   CIM      ([@bib5])
  3.04        PHM4204.69-PHM2343.25    NAM                                    SLB   GWAS     ([@bib40]; [@bib28])
  3.04        asg48-phi036             B73\*Mo17 (RILs)                       SLB   CIM      ([@bib3])
  3.04/3.05   umc010-umc 389b          F2:3 Lo951\*CML202                     NLB   CIM      ([@bib41])
  5.03/5.04   umc001-bnl5.40           F2:3 Lo951\*CML202                     NLB   CIM      ([@bib41])
  5.03-5.04   umc1171-bnlg1046         BC1F4, Y32\*Q11                        GLS   LA       ([@bib48])
  5.04        bnlg150                  Propietary F2                          GLS   CIM      ([@bib24])
  5.04        UMC43 UMC40              BC1S5, FR1141\*O61                     GLS   CIM      ([@bib12])
  5.04        UMC40 BNL7.71            BC1S5, FR1141\*O61                     GLS   CIM      ([@bib12])
  5.04        ASG71 CSU440             BC1S5, FR1141\*O61                     GLS   CIM      ([@bib12])
  5.04        BNL6.22-UMC51            HighLand\*LowLand                      NLB   CIM      ([@bib19])
  5.04        PHM532.23                NAM                                    NLB   GWAS     ([@bib37]; [@bib28])
  5.04        csu36a−bnl7.71           F3 D32\*D145                           NLB   CIM      ([@bib42])
  5.04        BNL5.7I-UMC51            B52\*Mo17 F2:3                         NLB   SIM      ([@bib14])
  5.04        bnl5.40-npi461           F2:3 Lo951\*CML202                     NLB   CIM      ([@bib41])
  5.04        PZA03049.24-PZB01017.1   NAM                                    SLB   GWAS     ([@bib40]; [@bib28])
  5.04/5.05   umc068-bnl5.24           F2:3 Lo951\*CML202                     NLB   CIM      ([@bib41])

Acronyms: CIM: composite interval mapping; GWAS: genome wide association study; JL: joint-linkage analysis; LA: Linkage analysis; MIM: multiple interval mapping; SIM: simple interval mapping. Adapted from ([@bib29]).

This study demonstrates the importance of independently evaluating QTL effects following their initial identification and before deploying them in a breeding program. In many cases where validation has been carried out (*e.g.*, [@bib26], [@bib27]), the validation rate was substantially higher than that reported here. It is nevertheless quite possible that QTL identified in single studies using a handful of environments may not be robust. Disease QTL, and QTL in general, often show environment-specific effects (*e.g.*, [@bib8]) and genetic background and epistasis are also common factors affecting QTL effects ([@bib16]; [@bib23]). This study further confirms the existence of QTL associated with multiple diseases that could be exploited in breeding programs. Future studies could fine map and investigate genes behind the MDR QTL to better understand the mechanisms that plants use to resistance against pathogens.
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